This unexpected pattern of pathway activation suggests a unique signaling profile in these cells, which may have important implications for understanding the disease mechanism and developing targeted therapies for ARID2-deficient TFE3-RCC. This evidence concerns the gene TFE3 and renal cell carcinoma.